Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
To explore the efficacy of triflusal in the attenuation of insulin resistance in human
obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic
agent (antiplatelet). The hypothesis is to explore if there is a reduction of obesity-induced
insulin resistance by triflusal.